Antibiotic resistance and prevalence of Stenotrophomonas maltophilia isolated from clinical samples.
5 affiliations
- 1Laboratory of Microbiology, Faculty of Medicine and Pharmacy, University Mohammed the First, Oujda, Morocco.
- 2Laboratory of Microbiology, Mohammed VI University Hospital, Oujda, Morocco.
- 3Laboratory of Bioresources, Biotechnology, Ethnopharmacology and Health, Faculty of Sciences, University Mohammed the First, 60000, Oujda, Morocco.
- 4Department of Bacteriology, Mohammed V Teaching Military Hospital, Rabat, Morocco.
- 5Epidemiology and Bacterial Resistance Research Team/BIO-INOVA Centre, Faculty of Medicine and Pharmacy, University Mohammed V, Rabat, Morocco.
Abstract
Stenotrophomonas maltophilia is an emerging non-fermenting Gram-negative bacillus increasingly implicated in healthcare-associated infections. Its remarkable ability to form biofilms on inert surfaces and invasive medical devices, together with its intrinsic and acquired resistance mechanisms, makes it a major therapeutic challenge in hospital settings. This study aimed to describe the epidemiological characteristics and antimicrobial susceptibility profile of S. maltophilia isolates recovered in our microbiology laboratory. A retrospective study was conducted on clinical isolates of S. maltophilia obtained from various clinical specimens. The bacterial examination was performed according to standard microbiological guidelines Over the study period, the prevalence of S. maltophilia isolates was 0.25% among all bacterial isolates (34 out of 13,959). Respiratory specimens were the most frequent source (23.53%, n=8), followed by blood cultures (17.65%, n=6). Most isolates originated from intensive care units (47.06%, n=16). Trimethoprim-sulfamethoxazole retained high efficacy with a susceptibility of 81.48%, whereas Minocycline demonstrated the highest activity, with a susceptibility rate of 100%. In contrast, the high resistance rates were observed for ceftazidime (61.90%). S. maltophilia represents an emerging nosocomial pathogen with significant therapeutic implications. Continuous monitoring of local resistance profiles, along with strengthened infection prevention measures and appropriate antibiotic use, is essential to limit the spread of resistant strains.
Related
- The role of the polysaccharide capsule as a novel virulence-associated trait of Stenotrophomonas maltophilia complex bacteria
- A Descriptive Observational Study of Real-Time TDM-Guided Aggressive PK/PD Target Attainment and Microbiological/Clinical Outcome in Patients with Stenotrophomonas maltophilia Bloodstream Infections and/or Pneumonia Treated with Continuous Infusion Cefiderocol.
- Whole-genome characterization of clinical Stenotrophomonas maltophilia in Lebanon: sequence types, resistome, and T6SS diversity
- The prevalence of neonatal sepsis caused by gram-negative bacteria and their antibiotic resistance patterns in Pakistan: a systematic review and meta-analysis
- Phenotypic Antimicrobial Resistance Patterns in E. coli, Salmonella, and Enterobacter Species Isolated from Broiler Chicken Meat in Mzimba, Malawi: Insights from the Multiple Antibiotic Resistance Index.
BibTeX
@article{lahmer2026antibiotic,
title = {{Antibiotic resistance and prevalence of Stenotrophomonas maltophilia isolated from clinical samples.}},
author = {Mohammed Lahmer and Abderrazak Saddari and Said Ezrari and Mostafa Elouennass and Adil Maleb},
journal = {Access microbiology},
year = {2026},
month = oct,
doi = {10.1099/acmi.0.001256.v3},
url = {https://europepmc.org/article/MED/42904165},
note = {CC BY},
}
RIS
TY - JOUR
TI - Antibiotic resistance and prevalence of Stenotrophomonas maltophilia isolated from clinical samples.
AU - Mohammed Lahmer
AU - Abderrazak Saddari
AU - Said Ezrari
AU - Mostafa Elouennass
AU - Adil Maleb
PY - 2026
DA - 2026/10/20
JO - Access microbiology
DO - 10.1099/acmi.0.001256.v3
UR - https://europepmc.org/article/MED/42904165
AB - Stenotrophomonas maltophilia is an emerging non-fermenting Gram-negative bacillus increasingly implicated in healthcare-associated infections. Its remarkable ability to form biofilms on inert surfaces and invasive medical devices, together with its intrinsic and acquired resistance mechanisms, makes it a major therapeutic challenge in hospital settings. This study aimed to describe the epidemiological characteristics and antimicrobial susceptibility profile of S. maltophilia isolates recovered in our microbiology laboratory. A retrospective study was conducted on clinical isolates of S. maltophilia obtained from various clinical specimens. The bacterial examination was performed according to standard microbiological guidelines Over the study period, the prevalence of S. maltophilia isolates was 0.25% among all bacterial isolates (34 out of 13,959). Respiratory specimens were the most frequent source (23.53%, n=8), followed by blood cultures (17.65%, n=6). Most isolates originated from intensive care units (47.06%, n=16). Trimethoprim-sulfamethoxazole retained high efficacy with a susceptibility of 81.48%, whereas Minocycline demonstrated the highest activity, with a susceptibility rate of 100%. In contrast, the high resistance rates were observed for ceftazidime (61.90%). S. maltophilia represents an emerging nosocomial pathogen with significant therapeutic implications. Continuous monitoring of local resistance profiles, along with strengthened infection prevention measures and appropriate antibiotic use, is essential to limit the spread of resistant strains.
SN - 2516-8290
ER -